Effects of Lactoferrin on Prevention of Acute Gastrointestinal Symptoms in Winter: A Randomized, Double-Blinded, Placebo-Controlled Trial for Staff of Kindergartens and Nursery Schools in Japan INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH,17(24) 2020(Dec.) Author:Mizuki Masaru, Tsukahara Teruomi, Oda Hirotsugu, Tanaka Miyuki, Yamauchi Koji, Abe Fumiaki, Nomiyama Tetsuo Keywords:lactoferrin; diarrhea; kindergarten; winter; subjective acute gastrointestinal symptoms;
Effects of Lactoferrin on Sleep Conditions in Children Aged 12-32 Months: A Preliminary, Randomized, Double-Blind, Placebo-Controlled Trial NATURE AND SCIENCE OF SLEEP,12:671-677 2020 Author:Miyakawa Momoko, Kubo Shutaro, Oda Hirotsugu, Motoki Noriko, Mizuki Masaru, Tsukahara Teruomi, Tanaka Miyuki, Yamauchi Koji, Abe Fumiaki, Nomiyama Tetsuo Keywords:lactoferrin; sleep; growing-up formula; children;
Effects of Lactoferrin-Fortified Formula on Acute Gastrointestinal Symptoms in Children Aged 12-32 Months: A Randomized, Double-Blind, Placebo-Controlled Trial FRONTIERS IN PEDIATRICS,8 2020 Author:Motoki Noriko, Mizuki Masaru, Tsukahara Teruomi, Miyakawa Momoko, Kubo Shutaro, Oda Hirotsugu, Tanaka Miyuki, Yamauchi Koji, Abe Fumiaki, Nomiyama Tetsuo Keywords:lactoferrin; infectious disease; diarrhea; growing-up formula; children;
Efeccts of 1-bromopropane on the vibrarion perception thresholds of male workers 33rd International Congress on Occupational Health（ICOH 2022） Presenter:Hirokazu Toubou, Masaru Mizuki, Kohei Hasegawa, Akito Takeuchi, Ryuta Abe, Teruomi Tsukahara and Tetsuo Nomiyam
MISC Effects of lactoferrin on sleep conditions in children aged 12-32 months: a preliminary, randomized, double-blind, placebo-controlled trial. Nat Sci Sleep,12:671 2020 Author:Miyakawa M, Kubo S, Oda H, Motoki N, Mizuki M, Tsukahara T, Tanaka M, Yamauchi K, Abe F, Nomiyama T Abstract:Purpose: To investigate preliminarily the effect of lactoferrin (LF)-fortified formula on sleep conditions in children.
Study design: A preliminary, randomized, double-blind, placebo-controlled trial.
Methods: Healthy children between the ages of 12 and 32 months who attended nursery schools in Japan were divided into two groups and assigned a placebo or LF (48 mg/day)-fortified formula. Children's sleep conditions were investigated before and after the 13-week intervention using the Japanese Sleep Questionnaire for Preschoolers (JSQ-P).
Results: Altogether, 109 participants were randomized. Eight participants were eliminated due to lost to follow-up, withdrawal of consent, and ineligibility, with 101 participants (placebo, n = 48; LF, n = 53) included in the full analysis set (FAS) and used for analysis. Wake-up time, bedtime, and nighttime sleep were comparable between the two groups before and after intervention. The change in total JSQ-P T scores tended to improve in the LF group (placebo vs LF: 0.5 ± 6.5 vs -1.9 ± 6.1, p = 0.074), in particular, morning symptoms significantly improved (grumpy in the morning, hard to wake-up, and hard to get out of bed) (placebo vs LF: 0.8 ± 6.2 vs -1.9 ± 6.2, p = 0.028). A better trend was also observed in the LF group regarding restless legs syndrome (RLS)-motor (rubs feet at night and touches feet at night) (placebo vs LF: 2.3 ± 10.7 vs -0.6 ± 13.5, p = 0.083) and insufficient sleep (stays up more than one hour later the day before a holiday and wakes up more than one hour later on a holiday) (placebo vs LF: 0.1 ± 9.8 vs -1.7 ± 8.8, p = 0.095). No adverse drug reactions were found.
Conclusion: LF intake may improve sleep condition, especially morning symptoms in children above one year of age.
Effects of lactoferrin-fortified formula on acute respiratory and gastrointestinal illnesses in children aged 12-32 months: A randomized, double-blind, placebo-controlled trial. Front. Pediatr.,８:233 2020 Author:Motoki N, Mizuki M, Tsukahara T, Miyakawa M, Kubo S, Oda H, Tanaka M, Yamauchi K, Abe F, Nomiyama T Abstract:Objective: We investigated the effects of lactoferrin (LF)-fortified formula on acute gastrointestinal and respiratory symptoms in children. Design: Randomized, double-blind, placebo-controlled trial. Setting and subjects: Children aged 12-32 months in Japan. Intervention: Intake of placebo or LF (48 mg/day)-fortified formula for 13 weeks. Primary endpoint: Prevalence of acute gastrointestinal and respiratory symptom. Results: One hundred nine participants were randomized. Eight participants were lost to follow-up, withdrew consent, or were deemed inappropriate for the trial, with 101 participants receiving complete analyses (placebo group, n = 48; LF group, n = 53). Outcomes: The prevalence of acute gastrointestinal symptoms was significantly less in the LF group (22/53 [41.5%]) than in the placebo group (30/48 [62.5%], p = 0.046). The total number of days having acute respiratory symptoms was significantly lower in the LF group (9.0) than in the placebo group (15.0, p = 0.030). Harms: The rate of adverse events was similar between the groups. No adverse drug reactions were found. Conclusions: LF intake decreased the prevalence of acute gastrointestinal symptoms in children aged 12-32 months.
Effects of lactoferrin on prevention of acute gastrointestinal symptoms in winter: A randomized, double-blinded, placebo-controlled trial for staff of kindergartens and nursery schools in Japan. Int J Environ Res Public Health,17(24):9582 2020 Author:Mizuki M, Tsukahara T, Oda H, Tanaka M, Yamauchi K, Abe F, Nomiyama T Abstract:This study investigated the preventive effects of lactoferrin (LF) on subjective acute gastrointestinal symptoms during the winter in a randomized, double-blinded, placebo-controlled parallel-group comparative trial. The eligible subjects were healthy adults working at kindergartens and nursery schools. We randomized the subjects to the Placebo group (0 mg/day), the Low LF group (200 mg/day), and the High LF group (600 mg/day) for 12 weeks. The prevalence of acute gastrointestinal symptoms was significantly lower in the High LF (13/112 vs. 26/116; p = 0.030) and the Low LF (13/107 vs. 26/116; p = 0.040) groups than in the Placebo group. The adjusted odds ratio for the prevalence of acute gastrointestinal symptoms was 2.78 (95% CI: 1.19–6.47) in the Placebo group compared with the High LF group. LF is useful to prevent acute gastrointestinal symptoms among childcare workers, who mainly consist of women.
研究者総覧
